^
    Back
    Association details:
    Biomarker:BCR-ABL1 G250E
    Cancer:Acute Lymphocytic Leukemia
    Drug:nilotinib (Bcr-abl inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Treatment recommendations based on BCR-ABL1 mutation profile…Nilotinib…Contraindicated mutations...T315I, Y253H, E255K/V, or F359V/C/I or G250E.